

Persistence of Individual Variations in Glycated Hemoglobin

Analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial

DARRELL M. WILSON, MD¹
 DONGYUAN XING, MPH²
 JING CHENG, MS²
 ROY W. BECK, MD, PHD²
 IRL HIRSCH, MD³
 CRAIG KOLLMAN, PHD²
 LORI LAFFEL, MD, MPH⁴
 JEAN M. LAWRENCE, SCD, MPH, MSSA⁵

NELLY MAURAS, MD⁶
 KATRINA J. RUEDY, MSPH²
 EVA TSALIKIAN, MD⁷
 HOWARD WOLPERT, MD⁸
 FOR THE JUVENILE DIABETES RESEARCH
 FOUNDATION CONTINUOUS GLUCOSE
 MONITORING STUDY GROUP*

OBJECTIVE—To determine the individual persistence of the relationship between mean sensor glucose (MG) concentrations and hemoglobin A_{1c} (A1C) from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (CGM) Randomized Trial.

RESEARCH DESIGN AND METHODS—MG was calculated using CGM data for 3 months before A1C measurements at 3, 6, 9, and 12 months for the CGM group and at 9 and 12 months for the control group. An MG-to-A1C ratio was included in analysis for subjects who averaged ≥ 4 days/week of CGM use.

RESULTS—Spearman correlations of the MG-to-A1C ratio between consecutive visits 3 months apart ranged from 0.70 to 0.79. The correlations for children and youth were slightly smaller than those for adults. No meaningful differences were observed by device type or change in A1C.

CONCLUSIONS—Individual variations in the rate of hemoglobin glycation are persistent and contribute to the inaccuracy in estimating MGs calculated from A1C levels.

Diabetes Care 34:1315–1317, 2011

Hemoglobin A_{1c} (A1C) is a time-honored gold standard measure of overall diabetes control, and A1C measurements serve as the targets for diabetes management (1). More recently, elevated A1C has been proposed as a more facile method for diagnosing diabetes (2). Additionally, A1C forms the basis for calculating the synthetic estimated average glucose (eAG) (3). Both of these

uses of A1C implicitly assume a consistent ratio between A1C and mean glucose (MG) over 2–3 months across individual subjects. Although the chemistry of glycation predicts a straightforward relationship between MG concentrations and A1C, many investigators have reported persistent individual variations in the rate of glycation among both subjects with and without diabetes. Investigators have

described fast or high glycaters as well as slow or low glycaters. Twin studies suggest a substantial heritable component (4).

Quantifying both the magnitude and the degree of persistence of the individual variation in the rate of erythrocyte glycation, however, has been hampered by limitations in accessing MG concentrations in groups of patients over a long period of time (5,6). In contrast, the recently completed Juvenile Diabetes Research Foundation (JDRF) Continuous Glucose Monitoring (CGM) trial provided data to closely examine the relationship between MG concentrations, measured in a near continuous fashion for 6–12 months, and the A1C values measured centrally in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) laboratory in patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS

The JDRF CGM randomized trial protocol has been described in detail previously (7–9). Major eligibility criteria included age ≥ 8 years, type 1 diabetes for ≥ 1 year, use of either an insulin pump or at least three daily insulin injections, and A1C $< 10.0\%$. Subjects were randomly assigned to either a CGM group or a control group for the first 6 months after which both groups used CGM for an additional 6 months. A1C was measured, and CGM data were downloaded at study visits occurring at 3, 6, 9, and 12 months from baseline. Thus subjects in the CGM group could contribute up to four A1C/CGM data points over 12 months, whereas those in the original control group could contribute two data points (when they had been using CGM at the 9- and 12-month visits).

All three commercially available glucose sensors were used, and subjects were instructed to wear the sensor on a continuous basis (7,8). A new sensor was inserted every 3–7 days with 4–15 calibrations over the sensor use according to the manufacturer's recommendations. A1C values were

From the ¹Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California; the ²Jaeb Center for Health Research, Tampa, Florida; the ³Diabetes Care Center, University of Washington, Seattle, Washington; the ⁴Pediatric, Adolescent, and Young Adult Section, Joslin Diabetes Center, Boston, Massachusetts; the ⁵Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; the ⁶Division of Endocrinology and Metabolism, Nemours Children's Clinic, Jacksonville, Florida; the ⁷Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa; and the ⁸Adult Section, Joslin Diabetes Center, Boston, Massachusetts.

Corresponding author: Roy W. Beck, jdrfapp@jaeb.org.

Received 31 August 2010 and accepted 10 March 2011.

DOI: 10.2337/dc10-1661. Clinical trial reg. no. NCT00406133, clinicaltrials.gov.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1661/-/DC1>.

*A complete list of the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group is available in the Supplementary Data online.

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

measured at the University of Minnesota using the Tosoh A1C 2.2 Plus Glycohemoglobin high-performance liquid chromatography analyzer (9).

MG was calculated using CGM data over the 91-day span before each visit, giving equal weight to each of the 24 h of the day. A data point was included in the analysis if the subject averaged ≥ 4 days per week of CGM use over the 91-day period and the subject had at least two 3-month CGM epochs followed by an A1C value. This criterion was met for 889 epochs in 311 of the 451 randomized subjects (153 had two epochs, 49 had three epochs, and 109 had four epochs). Within-subject persistency of the ratio of MG to A1C at different time points was assessed using Spearman correlation. A correlation coefficient based on ranks using the method of Magee (10) to account for repeated measures was computed. Results were similar using the hemoglobin glycation index (11) as an alternate measure of glycation, using both the regression equations from the JDRF randomized clinical trial data (7,8) and the American Diabetes Association Equation (12) (Supplementary Figs. A1 and A2). Subgroup analyses were performed by age, sex, device type, and change in A1C over the previous 3 months. The cohort did not contain enough non-White or Hispanic subjects to evaluate race/ethnicity.

RESULTS—The 311 subjects ranged in age from 8 to 73 years (mean \pm SD: 28 ± 17) at study entry, with 28% of subjects aged 8 to <15 years, 26% between 15 and <25 years, and 46% ≥ 25 years. Median (25th, 75th percentiles) duration of diabetes was 6 (3, 7), 8 (5, 12), and 23 (16, 32) years for these age-groups, respectively. Baseline A1C values ranged from 4.7 to 9.8% (mean \pm SD: 7.4 ± 0.8), and 56% were female.

The median (25th, 75th percentiles) of the MG-to-A1C ratio among all 889 epochs was 22.2 mg/dL per 1% (20.8, 23.5) ranging from 17.2 to 31.6. This distribution was steady over the 12-month course of the study (median values 22.4, 22.1, 22.1, and 22.1 at 3, 6, 9, and 12 months, respectively). Children and youth had larger ratios compared with adults (median 23.0 vs. 22.3 vs. 21.4 for subjects aged 8 to <15 , 15 to <25 , and ≥ 25 years, respectively; $P < 0.001$).

As shown in Fig. 1, subjects who were high glycaters (low MG-to-A1C ratio) during one 3-month epoch tended to be high glycaters during the subsequent




Figure 1—Comparison of the MG-to-A1C ratio from the same subject at different times. The MG-to-A1C ratios of subjects in 3-month periods were compared. The ratio at the earlier time is on the x-axis, and the ratio 3 months later is on the y-axis. Spearman correlation values are given for all four times.

3-month epoch. Correlations of the MG-to-A1C ratio between consecutive epochs ranged from 0.70 to 0.79. The correlation value from the repeated-measures model was 0.67. The correlation was comparable ($r = 0.75$) over a 9-month span from 3 to 12 months. Correlation values for children and youth were smaller than those in adults ranging from 0.57 to 0.71, 0.46 to 0.65, and 0.75 to 0.78 between consecutive epochs, for subjects aged 8 to <15 , 15 to <25 , and ≥ 25 years, respectively. All P values were < 0.001 . Correlations of the ratio of change in MG to change in A1C between successive visits ranged from 0.50 to 0.58 (Supplementary Fig. A3). No meaningful differences were observed by sex, device type, and treatment group (Supplementary Table A1 and Fig. A4).

CONCLUSIONS—Our results confirm the finding of others that individuals with type 1 diabetes persistently glycate hemoglobin at different rates. Many factors have been proposed to explain this (13,14), including conditions impacting erythrocyte life span, variation in erythrocyte glucose transport, and deglycation within the erythrocytes. In a recent meta-analysis of 10 genome-wide association studies examining nearly 15,000 nondiabetic adults of European descent, Wheeler et al. (15) found 10 loci associated with A1C, 2 of which were associated with iron homeostasis, perhaps altering erythrocyte life span.

Factors that alter the rate of hemoglobin glycation may be associated with the rate of glycation of other proteins,

thus impacting the likelihood of diabetes complications. Additionally, these persistent differences in the MG-to-A1C ratio imply that the MG concentration calculated from A1C measurement should be used with caution.

Acknowledgments—Financial support for this study was provided by the Juvenile Diabetes Research Foundation, Inc. (grant numbers 22-2006-1107, 22-2006-1117, 22-2006-1112, 22-2006-1123, and 01-2006-8031).

Continuous glucose monitors and sensors were purchased at a bulk discount price from DexCom (San Diego, CA), Medtronic MiniMed (Northridge, CA), and Abbott Diabetes Care (Alameda, CA). Home glucose meters and test strips were provided to the study by LifeScan and Abbott Diabetes Care.

DexCom, Medtronic MiniMed, Abbott Diabetes Care, and LifeScan had no involvement in the design, conduct, or analysis of the trial or the manuscript preparation.

Below is a listing of relationships of the investigators with companies that make products relevant to the manuscript between 1 July 2006 and present. Research funds listed below were provided to the legal entity that employs the individual and not directly to the individual.

I.H. reports having received consulting fees and travel reimbursement from Abbott Diabetes Care. C.K. reports having received consulting fees from Medtronic MiniMed. L.L. reports having received consulting fees from LifeScan, consulting fees and a speaker honorarium from Abbott Diabetes Care, consulting fees and research funding from Medtronic MiniMed, and consulting and speaker fees from Roche. No other potential conflicts of interest relevant to this article were reported.

The study was designed and conducted by the investigators. The writing group collectively wrote the manuscript and vouch for data. The investigators had complete autonomy to analyze and report the trial results. There were no agreements concerning confidentiality of data between the Juvenile Diabetes Research Foundation, Inc., the authors, or their institutions. The Jaeb Center for Health Research had full access to all data in the study and takes responsibility for the integrity of data and the accuracy of data analysis.

D.M.W. researched data, contributed to discussion, wrote the manuscript, and reviewed and edited the manuscript. D.X. contributed to discussion, wrote the manuscript, and reviewed and edited the manuscript. J.C. and R.W.B. contributed to discussion and reviewed and edited the manuscript. I.H. researched data, contributed to discussion, and reviewed and edited the manuscript. C.K. contributed to discussion and reviewed and edited the manuscript. L.L., J.M.L., N.M., K.J.R., E.T., and H.W. researched data, contributed to discussion, and reviewed and edited the manuscript.

The JDRF CGM Study Group would like to recognize the efforts of the subjects and their families and thank them for their participation.

References

- American Diabetes Association. Standards of clinical practice recommendations—2009. *Diabetes Care* 2009;32(Suppl. 1): S13–S61
- International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1327–1334
- American Diabetes Association. Estimated average glucose, eAG [article online], 2009. Available from <http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/estimated-average-glucose.html>. Accessed 1 June 2010
- Cohen RM, Snieder H, Lindsell CJ, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1C in nondiabetic twins. *Diabetes Care* 2006;29:1739–1743
- Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. *Diabetes Care* 2001;24:1858–1862
- Fiallo-Scharer R; Diabetes Research in Children Network Study Group. Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes. *J Clin Endocrinol Metab* 2005;90:3387–3391
- JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. *Diabetes Technol Ther* 2008;10:310–321
- Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N Engl J Med* 2008;359:1464–1476
- Gibb I, Parnham A, Fonfrède M, Lecock F. Multicenter evaluation of Tosoh glycohemoglobin analyzer. *Clin Chem* 1999; 45:1833–1841
- Magee L. R2 measures based on Wald and likelihood ratio joint significance tests. *Am Stat* 1990;44:250–253
- McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1C predicts risk of retinopathy and nephropathy in type 1 diabetes. *Diabetes Care* 2004; 27:1259–1264
- Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1C-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008; 31:1473–1478
- Herman WH. Diabetes epidemiology: guiding clinical and public health practice: the Kelly West Award Lecture, 2006. *Diabetes Care* 2007;30:1912–1919
- Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1C, and advanced glycation end products associated with diabetes complications. *J Diabetes Sci Tech* 2009;3:635–643
- Wheeler E, Soranzo N, Sanna S, et al.; MAGIC Investigators. A large genome-wide association study of glycosylated hemoglobin identifies ten common variants not mediated through BMI. *Genet Epidemiol* 2009;33:758–759